Insider transactions

EDGAR

AbbVie Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
7 transactions, 119,608 shares
Sum of shares × price per share: 30,847,936.53

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 97

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-16 Filed 2026-11-18SALEKI AZITA Officer: EVP, CHIEF OPERATIONS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)23,93561.36
1,468,651.6

Derived: shares × price per share. Exact value 1468651.60.

221,729Direct (D) No— Open filing 0001563545-26-000006 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-18SALEKI AZITA Officer: EVP, CHIEF OPERATIONS OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)13,481298.55
4,024,752.55

Derived: shares × price per share. Exact value 4024752.55.

208,248Direct (D) No
F1
  • F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.55 to $298.64, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001563545-26-000006 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-18SALEKI AZITA Officer: EVP, CHIEF OPERATIONS OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to Buy) — underlying Common Stock (13,481) — exercise price 61.36
Disposed (D)13,4810—23,935Direct (D) No
F3
  • F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,957 on February 16, 2018, 15,956 on February 16, 2019, and 15,957 on February 16, 2020.
Open filing 0001563545-26-000006 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
G

Bona fide gift

Common Stock, $0.01 par value
Disposed (D)3,4500—79,721Direct (D) No— Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)16,070114.36
1,837,765.2

Derived: shares × price per share. Exact value 1837765.20.

99,241Direct (D) No— Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)24,54993.50
2,295,331.5

Derived: shares × price per share. Exact value 2295331.50.

123,790Direct (D) No— Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)40,619293.60
11,925,738.4

Derived: shares × price per share. Exact value 11925738.40.

83,171Direct (D) No
F1
  • F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to Buy) — underlying Common Stock (16,070) — exercise price 114.36
Disposed (D)16,0700—0Direct (D) No
F3
  • F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021.
Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to Buy) — underlying Common Stock (24,549) — exercise price 93.50
Disposed (D)24,5490—24,550Direct (D) No
F4
  • F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.
Open filing 0001761675-26-000007 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Quaggin Susan E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (59) — exercise price 261.59
Acquired (A)59261.59
15,433.81

Derived: shares × price per share. Exact value 15433.81.

918Direct (D) No
F1, F2
  • F1 Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001997505-26-000010 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02RAPP EDWARD J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (129) — exercise price 261.59
Acquired (A)129261.59
33,745.11

Derived: shares × price per share. Exact value 33745.11.

29,568Direct (D) No
F1, F2
  • F1 Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001171780-26-000014 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Donoghoe Nicholas Officer: EVP, CHIEF BUS/STRAT OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)32,71079.02
2,584,744.2

Derived: shares × price per share. Exact value 2584744.20.

107,140Direct (D) No— Open filing 0001762951-26-000006 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Donoghoe Nicholas Officer: EVP, CHIEF BUS/STRAT OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)32,710250
8,177,500

Derived: shares × price per share. Exact value 8177500.

74,430Direct (D) No— Open filing 0001762951-26-000006 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-18Donoghoe Nicholas Officer: EVP, CHIEF BUS/STRAT OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to buy) — underlying Common Stock (32,710) — exercise price 79.02
Disposed (D)32,7100—0Direct (D) No
F1
  • F1 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.
Open filing 0001762951-26-000006 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Quaggin Susan E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (62) — exercise price 251.64
Acquired (A)62251.64
15,601.68

Derived: shares × price per share. Exact value 15601.68.

853Direct (D) No
F1, F2
  • F1 Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001997505-26-000008 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02RAPP EDWARD J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (134) — exercise price 251.64
Acquired (A)134251.64
33,719.76

Derived: shares × price per share. Exact value 33719.76.

29,236Direct (D) No
F1, F2
  • F1 Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001171780-26-000012 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12FALK THOMAS J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—2,321Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001222890-26-000003 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12Quaggin Susan E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—3,643Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001997505-26-000006 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12MEYER MELODY B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—17,616Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001706126-26-000002 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12FREYMAN THOMAS C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—127,869Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001239126-26-000002 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12Hart Brett J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—20,590Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001466338-26-000003 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12AUSTIN ROXANNE S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—39,576Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001061632-26-000004 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12RAPP EDWARD J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—45,964Direct (D) No
F1, F2
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
  • F2 Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly.
Open filing 0001171780-26-000010 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12Davis Jennifer L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—3,643Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001916665-26-000002 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12WADDELL FREDERICK H Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—30,076Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001223690-26-000004 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12BURNSIDE WILLIAM H.L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—28,076Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001563579-26-000002 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-12Roberts Rebecca B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $0.01 par value
Acquired (A)1,1180—14,846Direct (D) No
F1
  • F1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the Program). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
Open filing 0001355580-26-000002 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02RAPP EDWARD J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (155) — exercise price 217.49
Acquired (A)155217.49
33,710.95

Derived: shares × price per share. Exact value 33710.95.

28,865Direct (D) No
F1, F2
  • F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001171780-26-000006 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Alpern Robert J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (35) — exercise price 217.49
Acquired (A)35217.49
7,612.15

Derived: shares × price per share. Exact value 7612.15.

10,369Direct (D) No
F1, F2
  • F1 Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001448074-26-000007 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Quaggin Susan E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Equivalent Units — underlying Common Stock (71) — exercise price 217.49
Acquired (A)71217.49
15,441.79

Derived: shares × price per share. Exact value 15441.79.

784Direct (D) No
F1, F2
  • F1 Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
  • F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Open filing 0001997505-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-06Purdue David Ryan Officer: SVP, Controller
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)5,230233.56
1,221,518.8

Derived: shares × price per share. Exact value 1221518.80.

2,654Direct (D) No— Open filing 0002057696-26-000008 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-03Siatis Perry C Officer: EVP, GC AND SECRETARY
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)5,777233.51
1,348,987.27

Derived: shares × price per share. Exact value 1348987.27.

17,510Direct (D) Yes
F1
  • F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001951400-26-000006 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-03Siatis Perry C Officer: EVP, GC AND SECRETARY
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)10,291234.66
2,414,886.06

Derived: shares × price per share. Exact value 2414886.06.

7,219Direct (D) Yes
F2
  • F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001951400-26-000006 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-03Siatis Perry C Officer: EVP, GC AND SECRETARY
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)2,600235.26
611,676

Derived: shares × price per share. Exact value 611676.00.

4,619Direct (D) Yes
F3
  • F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001951400-26-000006 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-11Purdue David Ryan Officer: SVP, Controller
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)2,108232.08
489,224.64

Derived: shares × price per share. Exact value 489224.64.

8,468Direct (D) No— Open filing 0002057696-26-000010 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-06Crum Demetris D Officer: EVP, CHIEF HR OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)1,594232.08
369,935.52

Derived: shares × price per share. Exact value 369935.52.

7,914Direct (D) No— Open filing 0002078592-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Michael Robert A. Director · Officer: CHAIRMAN OF THE BOARD AND CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)36,523232.08
8,476,257.84

Derived: shares × price per share. Exact value 8476257.84.

178,737Direct (D) No— Open filing 0001699914-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Purdue David Ryan Officer: SVP, Controller
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)2,692232.08
624,759.36

Derived: shares × price per share. Exact value 624759.36.

7,884Direct (D) No— Open filing 0002057696-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03SALEKI-GERHARDT AZITA Officer: EVP, CHIEF OPERATIONS OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)16,309232.08
3,784,992.72

Derived: shares × price per share. Exact value 3784992.72.

197,794Direct (D) No— Open filing 0001563545-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Siatis Perry C Officer: EVP, GC AND SECRETARY
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)14,850232.08
3,446,388

Derived: shares × price per share. Exact value 3446388.00.

23,287Direct (D) Yes— Open filing 0001951400-26-000006 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Reents Scott T Officer: EVP, CHIEF FINANCIAL OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)21,638232.08
5,021,747.04

Derived: shares × price per share. Exact value 5021747.04.

38,777Direct (D) No— Open filing 0001937048-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Donoghoe Nicholas Officer: EVP, CHIEF BUS/STRAT OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)12,874232.08
2,987,797.92

Derived: shares × price per share. Exact value 2987797.92.

74,430Direct (D) No— Open filing 0001762951-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Thakkar Roopal Officer: EVP, RD and CSO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)8,037232.08
1,865,226.96

Derived: shares × price per share. Exact value 1865226.96.

52,376Direct (D) No— Open filing 0002004979-26-000004 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-03Stewart Jeffrey Ryan Officer: EVP, CHIEF COMMERCIAL OFFICER
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $0.01 par value
Disposed (D)23,812232.08
5,526,288.96

Derived: shares × price per share. Exact value 5526288.96.

83,171Direct (D) No— Open filing 0001761675-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)7,314149.62
1,094,320.68

Derived: shares × price per share. Exact value 1094320.68.

45,451Direct (D) Yes— Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)7,775175.28
1,362,802

Derived: shares × price per share. Exact value 1362802.00.

53,226Direct (D) Yes— Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $0.01 par value
Acquired (A)7,292192.86
1,406,335.12

Derived: shares × price per share. Exact value 1406335.12.

60,518Direct (D) Yes— Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
S

Open market or private sale of non-derivative or derivative security

Common Stock, $0.01 par value
Disposed (D)22,381230
5,147,630

Derived: shares × price per share. Exact value 5147630.

38,137Direct (D) Yes— Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to buy) — underlying Common Stock (7,314) — exercise price 149.62
Disposed (D)7,314149.62
1,094,320.68

Derived: shares × price per share. Exact value 1094320.68.

0Direct (D) Yes
F1
  • F1 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.
Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Siatis Perry C Officer: EVP, GC AND SECRETARY
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Option (Right to buy) — underlying Common Stock (7,775) — exercise price 175.28
Disposed (D)7,775175.28
1,362,802

Derived: shares × price per share. Exact value 1362802.00.

7,774Direct (D) Yes
F2
  • F2 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.
Open filing 0001951400-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 4,383

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
BlackRock, Inc. Partly reported under another manager148,974,939 SH38,970,354,223 dollarsLower by 513,473 Prior quarter: 149,488,412Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 115,676,728 SH30,259,875,278 dollarsHigher by 280,630 Prior quarter: 115,396,098Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager82,815,387 SH21,663,677,085 dollarsHigher by 218,639 Prior quarter: 82,596,748Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 49,001,331 SH12,818,258,176 dollarsHigher by 523,335 Prior quarter: 48,477,996Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager47,503,777 SH12,404,019,552 dollarsHigher by 505,344 Prior quarter: 46,998,433Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager45,333,436 SH11,935,841,059 dollarsLower by 2,529,360 Prior quarter: 47,862,796Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager38,398,732 SH10,044,725,187 dollarsLower by 502,269 Prior quarter: 38,901,001Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Capital Research Global Investors Partly reported under another manager31,115,872 SH8,139,628,876 dollarsHigher by 1,014,321 Prior quarter: 30,101,551Open filing 0001422848-26-000129 Filed 2026-11-12 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager26,386,673 SH6,902,489,822 dollarsHigher by 5,148,909 Prior quarter: 21,237,764Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Capital World Investors Partly reported under another manager20,653,641 SH5,402,940,209 dollarsHigher by 1,474,675 Prior quarter: 19,178,966Open filing 0001422849-26-000169 Filed 2026-11-12 Dispute this row
FMR LLC Partly reported under another manager20,186,300 SH5,280,534,136 dollarsLower by 587,486 Prior quarter: 20,773,786Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager19,762,425 SH5,169,652,756 dollarsLower by 796,022 Prior quarter: 20,558,447Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager19,697,133 SH5,807,333,774 dollarsLower by 228,099 Prior quarter: 19,925,232Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Partly reported under another manager19,665,501 SH5,144,298,408 dollarsHigher by 5,397,804 Prior quarter: 14,267,697Open filing 0000861177-26-000005 Filed 2026-11-16 Dispute this row
Capital International Investors Partly reported under another manager16,171,164 SH4,230,994,162 dollarsHigher by 532,533 Prior quarter: 15,638,631Open filing 0001562230-26-000136 Filed 2026-11-12 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager15,028,012 SH3,931,177,396 dollarsHigher by 2,174,644 Prior quarter: 12,853,368Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager14,759,347 SH3,860,898 dollarsHigher by 10,278 Prior quarter: 14,749,069Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager14,369,942 SH3,759,033,203 dollarsLower by 1,921,688 Prior quarter: 16,291,630Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Partly reported under another manager13,001,868 SH3,401,617,002 dollarsHigher by 87,638 Prior quarter: 12,914,230Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager11,920,186 SH3,118,201,456 dollarsLower by 924,934 Prior quarter: 12,845,120Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Amundi Partly reported under another manager11,720,448 SH3,065,958,038 dollarsHigher by 1,681,159 Prior quarter: 10,039,289Open filing 0001172661-26-004884 Filed 2026-11-06 Dispute this row
Legal General Group Plc Partly reported under another manager11,509,934 SH3,010,883,630 dollarsLower by 38,119 Prior quarter: 11,548,053Open filing 0001495115-26-000075 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager11,373,579 SH2,976,125,730 dollarsLower by 145,928 Prior quarter: 11,519,507Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager11,124,253 SH2,909,993,344 dollarsHigher by 351,304 Prior quarter: 10,772,949Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager10,705,904 SH2,800,557,428 dollarsHigher by 5,650,315 Prior quarter: 5,055,589Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
Fisher Asset Management, LLC Partly reported under another manager10,063,539 SH2,632,521,480 dollarsHigher by 565,569 Prior quarter: 9,497,970Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO 9,995,595 SH2,614,747,696 dollarsHigher by 55,804 Prior quarter: 9,939,791Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager9,906,657 SH2,591,482,470 dollarsLower by 503,502 Prior quarter: 10,410,159Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
Nuveen, LLC Partly reported under another manager9,735,091 SH2,546,602,342 dollarsHigher by 225,100 Prior quarter: 9,509,991Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager9,079,944 SH2,375,222,210 dollarsHigher by 62,364 Prior quarter: 9,017,580Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager7,718,544 SH2,019,094,000 dollarsLower by 445,262 Prior quarter: 8,163,806Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
Invesco Ltd. Partly reported under another manager6,695,576 SH1,751,495,840 dollarsLower by 419,206 Prior quarter: 7,114,782Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager6,637,840 SH1,736,522,586 dollarsLower by 599,021 Prior quarter: 7,236,861Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Mirabaud Asset Management Ltd 6,200,000 PRN1,632,398 dollarsNot in the prior quarter’s filings read Open filing 0001680493-26-000018 Filed 2026-11-09 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager5,990,058 SH1,567,106,422 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Partly reported under another manager5,892,808 SH1,541,499,645 dollarsUnchanged Prior quarter: 5,892,808Open filing 0000315032-26-000005 Filed 2026-11-12 Dispute this row
Swiss National Bank 4,832,410 SH1,264,110,132 dollarsLower by 156,300 Prior quarter: 4,988,710Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
Boston Partners Partly reported under another manager4,827,961 SH1,264,122,966 dollarsHigher by 43,645 Prior quarter: 4,784,316Open filing 0001386060-26-000054 Filed 2026-11-10 Dispute this row
ENVESTNET ASSET MANAGEMENT INC 4,795,011 SH1,254,324,907 dollarsLower by 91,659 Prior quarter: 4,886,670Open filing 0001214659-26-014231 Filed 2026-11-16 Dispute this row
Mitsubishi UFJ Asset Management Co., Ltd. Partly reported under another manager4,596,807 SH1,202,478,288 dollarsHigher by 256,087 Prior quarter: 4,340,720Open filing 0001193125-26-447983 Filed 2026-11-05 Dispute this row
HSBC HOLDINGS PLC Partly reported under another manager4,356,269 SH1,141,215,137 dollarsHigher by 224,632 Prior quarter: 4,131,637Open filing 0000873630-26-000005 Filed 2026-11-16 Dispute this row
ALLIANCEBERNSTEIN L.P. Partly reported under another manager4,344,902 SH1,136,608,860 dollarsHigher by 252,567 Prior quarter: 4,092,335Open filing 0001109448-26-000342 Filed 2026-11-16 Dispute this row
VANGUARD ASSET MANAGEMENT, Ltd 4,298,191 SH1,124,363,784 dollarsHigher by 302,749 Prior quarter: 3,995,442Open filing 0001680208-26-000018 Filed 2026-11-13 Dispute this row
BARCLAYS PLC Partly reported under another manager4,261,508 SH1,114,767,876 dollarsLower by 754,007 Prior quarter: 5,015,515Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
LPL Financial LLC 4,142,781 SH1,083,709,960 dollarsHigher by 46,458 Prior quarter: 4,096,323Open filing 0001403438-26-000005 Filed 2026-11-06 Dispute this row
National Pension Service 4,043,565 SH1,057,756,168 dollarsHigher by 33,992 Prior quarter: 4,009,573Open filing 0001193125-26-456954 Filed 2026-11-12 Dispute this row
PNC Financial Services Group, Inc. Partly reported under another manager4,007,550 SH1,048,334,977 dollarsHigher by 104 Prior quarter: 4,007,446Open filing 0001193125-26-450808 Filed 2026-11-06 Dispute this row
NORDEA INVESTMENT MANAGEMENT AB Partly reported under another manager3,933,975 SH1,038,687,419 dollarsLower by 871,367 Prior quarter: 4,805,342Open filing 0001218210-26-000023 Filed 2026-11-09 Dispute this row
Vanguard Global Advisers, LLC 3,909,417 SH1,022,664,393 dollarsHigher by 80,098 Prior quarter: 3,829,319Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main Partly reported under another manager3,846,731 SH1,006,270,573 dollarsHigher by 961,174 Prior quarter: 2,885,557Open filing 0000905148-26-004847 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • NORGES BANK 25,554,538 SH
  • Sixth Street Partners Management Company, L.P. 12,914,230 SH
  • Jupiter Topco LLC 6,201,973 SH
  • SG Americas Securities, LLC 3,984,924 SH
  • SG Americas Securities, LLC 1,265,900 SH
  • Balyasny Asset Management L.P. 622,946 SH
  • HM PAYSON CO 596,837 SH
  • Tredje AP-fonden 548,411 SH
  • CAPITAL ADVISORS INC/OK 447,129 SH
  • NewEdge Wealth, LLC 422,116 SH
  • VOLORIDGE INVESTMENT MANAGEMENT, LLC 380,290 SH
  • Hudson Bay Capital Management LP 380,000 SH
  • Point72 Asset Management, L.P. 366,836 SH
  • CURA WEALTH ADVISORS, LLC 289,872 SH
  • RNC CAPITAL MANAGEMENT LLC 236,727 SH
  • Quadrature Capital Ltd 212,852 SH
  • Pacer Advisors, Inc. 201,334 SH
  • JOHNSON INVESTMENT COUNSEL INC 155,264 SH
  • World Investment Advisors 121,763 SH
  • Miramar Capital, LLC 104,867 SH
  • Venturi Wealth Management, LLC 100,019 SH
  • Prospera Financial Services Inc 96,118 SH
  • Stillwater Capital Advisors, LLC 89,325 SH
  • Envestnet Portfolio Solutions, Inc. 89,324 SH
  • Y-Intercept (Hong Kong) Ltd 74,248 SH
  • ST GERMAIN D J CO INC 68,593 SH
  • Summit Trail Advisors, LLC 66,840 SH
  • Arkadios Wealth Advisors 65,660 SH
  • Entropy Technologies, LP 64,317 SH
  • Arvest Bank Trust Division 60,049 SH
  • WEBSTER BANK, N. A. 54,925 SH
  • Weiss Asset Management LP 50,316 SH
  • CAISSE DES DEPOTS ET CONSIGNATIONS 50,000 SH
  • CAPITAL FUND MANAGEMENT S.A. 47,541 SH
  • Caption Management, LLC 47,000 SH
  • CIBC Bancorp USA Inc. 45,000 SH
  • ROWLANDMILLER PARTNERS.ADV 43,246 SH
  • Laurion Capital Management LP 42,168 SH
  • KEYNOTE FINANCIAL SERVICES LLC 38,262 SH
  • Wellington Shields Co., LLC 30,747 SH
  • PLATINUM INVESTMENT MANAGEMENT LTD 30,102 SH
  • TRANSCEND CAPITAL ADVISORS, LLC 29,656 SH
  • Seascape Capital Management 28,801 SH
  • SPIREPOINT PRIVATE CLIENT, LLC 26,767 SH
  • Thomasville National Bank 26,575 SH
  • Phocas Financial Corp. 26,200 SH
  • Front Row Advisors LLC 24,207 SH
  • D. E. Shaw Co., Inc. 23,600 SH
  • DoubleLine ETF Adviser LP 19,587 SH
  • Maven Securities LTD 18,400 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–50 of 133

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Pete Sessions (TX17)2026-09-14Sale$15,001 - $50,0002026-09-18
Hon. Josh Gottheimer (NJ05)2026-05-05Sale$1,001 - $15,000JT2026-06-03
Hon. Julie Johnson (TX32)2025-12-18Sale$1,001 - $15,000JT2026-01-15
Hon. Julia Letlow (LA05)2025-12-08Sale$1,001 - $15,0002026-01-13
Hon. Julia Letlow (LA05)2024-10-23Purchase$1,001 - $15,0002026-01-13
Hon. Julia Letlow (LA05)2025-01-24Sale$1,001 - $15,0002026-01-13
Hon. Julia Letlow (LA05)2025-04-28Purchase$1,001 - $15,0002026-01-13
Hon. Julie Johnson (TX32)2025-11-13Sale (partial)$1,001 - $15,000JT2025-12-11
Hon. Lisa McClain (MI09)2025-10-30Sale$1,001 - $15,000SP2025-11-21
Hon. Lisa McClain (MI09)2025-10-30Purchase$1,001 - $15,000SP2025-11-21
Hon. Lisa McClain (MI09)2025-10-31Sale$1,001 - $15,000SP2025-11-21
Hon. Julie Johnson (TX32)2025-08-14Sale (partial)$1,001 - $15,000JT2025-09-11
Hon. Ritchie John Torres (NY15)2024-09-26Purchase$1,001 - $15,0002025-08-20
Hon. Ritchie John Torres (NY15)2025-07-11Sale$1,001 - $15,0002025-08-20
Hon. Marjorie Taylor Greene (GA14)2025-08-04Purchase$1,001 - $15,0002025-08-15
Hon. Lisa McClain (MI09)2025-06-17Purchase$1,001 - $15,000SP2025-08-13
Hon. Lisa McClain (MI09)2025-07-22Sale (partial)$1,001 - $15,000SP2025-08-13
Hon. Lisa McClain (MI09)2025-07-22Purchase$1,001 - $15,000SP2025-08-13
Hon. Josh Gottheimer (NJ05)2025-05-22Purchase$1,001 - $15,000JT2025-06-11
Hon. Rob Bresnahan (PA08)2025-05-15Purchase$1,001 - $15,0002025-06-09
Hon. Josh Gottheimer (NJ05)2025-04-03Purchase$1,001 - $15,000JT2025-05-14
Hon. Josh Gottheimer (NJ05)2025-04-01Purchase$1,001 - $15,000JT2025-05-14
Hon. Josh Gottheimer (NJ05)2025-04-17Sale$1,001 - $15,000JT2025-05-14
Hon. Jared Moskowitz (FL23)2025-04-07Purchase$1,001 - $15,0002025-05-09
Hon. Jefferson Shreve (IN06)2025-04-17Sale$50,001 - $100,0002025-05-08
Hon. Rob Bresnahan (PA08)2025-04-08Sale$1,001 - $15,0002025-05-08
Hon. Marjorie Taylor Greene (GA14)2025-05-05Purchase$1,001 - $15,0002025-05-06
Hon. Dwight Evans (PA03)2025-04-03Sale (partial)$1,001 - $15,0002025-04-17
Hon. Rob Bresnahan (PA08)2025-02-25Purchase$1,001 - $15,0002025-03-27
Hon. Marjorie Taylor Greene (GA14)2025-03-17Purchase$1,001 - $15,0002025-03-19
Hon. Jefferson Shreve (IN06)2025-02-24Purchase$50,001 - $100,0002025-03-09
Hon. Jared Moskowitz (FL23)2025-01-15Purchase$1,001 - $15,000DC2025-02-10
Hon. Jared Moskowitz (FL23)2025-01-15Purchase$1,001 - $15,0002025-02-10
Hon. Virginia Foxx (NC05)2024-12-06Purchase$1,001 - $15,0002025-01-06
Hon. Marjorie Taylor Mrs Greene (GA14)2024-11-20Purchase$1,001 - $15,0002024-11-21
Hon. John James (MI10)2024-09-04Sale$1,001 - $15,0002024-09-06
Hon. John James (MI10)2023-11-10Purchase$1,001 - $15,0002024-09-02
Hon. Kathy Manning (NC06)2024-07-02Purchase$1,001 - $15,000SP2024-08-16
Hon. Michael C. Burgess (TX26)2024-04-10Sale (partial)$1,001 - $15,0002024-05-02
Hon. Kathy Manning (NC06)2024-01-23Purchase$1,001 - $15,000SP2024-02-06
Hon. Michael C. Burgess (TX26)2023-12-08Sale$1,001 - $15,0002023-12-18
Hon. Josh Gottheimer (NJ05)2023-11-08Sale$1,001 - $15,000JT2023-12-08
Hon. Greg Stanton (AZ04)2023-10-24Sale$1,001 - $15,000SP2023-11-09
Hon. Greg Stanton (AZ04)2023-09-26Purchase$1,001 - $15,000SP2023-11-09
Hon. Robert J. Wittman (VA01)2023-09-28Sale$1,001 - $15,0002023-10-19
Hon. Lois Frankel (FL22)2023-09-06Purchase$1,001 - $15,0002023-10-10
Hon. Lois Frankel (FL22)2023-08-30Purchase$1,001 - $15,0002023-10-10
Hon. Lois Frankel (FL22)2023-09-08Sale$1,001 - $15,0002023-10-10
Hon. Michael C. Burgess (TX26)2023-08-14Sale$15,001 - $50,000SP2023-09-05
Hon. Michael Patrick Guest (MS03)2023-08-07Purchase$1,001 - $15,000SP2023-08-23

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Vanguard Capital Management Common Stock7.51132,924,05803/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100119-26-000126 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 12Open filing 0000102909-26-000503 Dispute this row
The Vanguard Group Common Stock10.03177,266,70306/30/2025 Filed 2025-07-07SCHEDULE 13G/AAmendment 11Open filing 0000932471-25-000695 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,735,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015151,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to AbbVie Inc.